<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088620</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_AG47</org_study_id>
    <secondary_id>2009-014677-41</secondary_id>
    <secondary_id>GMIHO-006/2008</secondary_id>
    <nct_id>NCT01088620</nct_id>
  </id_info>
  <brief_title>Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to estimate the therapeutic efficacy of the experimental
      targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and
      cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage
      IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the
      progression free survival rate at 6 months is improved by the targeted regimen.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has
    not yet been verified
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the tumour response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects / toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of inoperable stage IIIB or IV primary pulmonary
             nonsquamous NSCLC (according to UICC staging valid until 2008)

          -  Sufficient representative sample material for KRAS analysis

          -  Wild-type KRAS

          -  Informed consent of the patient

          -  Aged at least 18 years

          -  WHO Performance Status 0-2

          -  At least one unidimensional, measurable tumour parameter according to RECIST

          -  Life expectancy of al least 12 weeks

          -  Adequate haematological, hepatic, renal and metabolic function parameters:

               -  Leukocytes &gt; 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Creatinine
                  clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of normal

               -  Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in
                  absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver
                  metastases, AP ≤ 5 x upper limit of normal

               -  Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal

        Exclusion Criteria:

          -  Prior chemotherapy

          -  Clinically manifest, uncontrolled brain metastases

          -  Prior radiotherapy of the parameters to be measured

          -  Peripheral neuropathy NCI grade &gt; 1

          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months
             after the end of treatment.

          -  Subject (male or female) is not willing to use highly effective methods of
             contraception (per institutional standard) during treatment and for 6 months (male or
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device
             or barrier method in conjunction with spermicidal jelly).

          -  Serious concurrent diseases.

          -  Major surgery within the last 4 weeks before recruitment

          -  On-treatment participation in a clinical study in the period 30 days prior to
             inclusion.

          -  Clinically significant cardiovascular disease in (incl. myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 1 year before enrolment.

          -  Ongoing or active infection, including active tuberculosis or known infection with
             human immunodeficiency virus.

          -  Superior vena cava syndrome contraindicating hydration.

          -  History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  Patient with mild to moderate renal insufficiency who are unable to interrupt
             salicylates (like aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDS) for
             a 5-day period starting 2 days before administration of pemetrexed (8-day period for
             long-acting agents such as piroxicam). Exception: Low dose aspirin (acetyl salicylic
             acid) intake up to 150 mg per day is permitted without interruption.

          -  Presence of clinically significant third-space fluid collections, for example, ascites
             or pleural effusions that cannot be controlled by drainage or other procedures

          -  Inability or unwillingness to take folic acid, vitamin B12 supplementation or
             dexamethasone (or equivalent corticosteroid); or any other inability to comply with
             protocol or study related procedures

          -  Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except
             non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is
             continuously disease-free

          -  Known allergic reactions on study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Schütte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Martha-Maria Halle-Dölau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin Medizinische Klinik m. S. Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring - Lungenklinik Heckeshorn</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus gGmbH</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Carl Gustav Carus der Technischen Universität Dresden Medizinische Klinik 1</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Duisburg/St. Johannes-Hospital</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Großhansdorf GmbH Onkologischer Schwerpunkt</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus - Martha-Maria Halle-Dölau GmbH</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin I</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dr. Stauch</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln, Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK-SH, Campus Lübeck, Med. Klinik III</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU-Klinikum der Universität München, Medizinische Klinik München-Innenstadt</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologianova GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Ulm, Klinik für Innere Medizin II, Pneumologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Stage IIIb or IV</keyword>
  <keyword>Nonsquamous</keyword>
  <keyword>KRAS-Wildtype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

